LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.

Karaźniewicz-Łada, Marta / Krzyżańska, Dagmara / Danielak, Dorota / Rzeźniczak, Janusz / Główka, Franciszek / Słomczyński, Marek / Burchardt, Paweł

European journal of clinical pharmacology

2020  Volume 76, Issue 3, Page(s) 419–430

Abstract: Purpose: Impaired antiplatelet effect of clopidogrel (CLP) can result from drug-drug interactions and genetic polymorphisms of drug-metabolizing enzymes. The aim of the study was to evaluate the effect of genetic polymorphisms of ABCB1 and the selected ... ...

Abstract Purpose: Impaired antiplatelet effect of clopidogrel (CLP) can result from drug-drug interactions and genetic polymorphisms of drug-metabolizing enzymes. The aim of the study was to evaluate the effect of genetic polymorphisms of ABCB1 and the selected cytochrome P450 isoenzymes on the pharmacodynamics and pharmacokinetics of CLP and its metabolites in patients co-treated with atorvastatin or rosuvastatin.
Methods: The study involved 50 patients after coronary angiography/angioplasty treated with CLP and atorvastatin (n = 25) or rosuvastatin (n = 25) for at least 6 months. Plasma concentrations of CLP, diastereoisomers of thiol metabolite (inactive H3 and active H4), and inactive CLP carboxylic acid metabolite were measured by UPLC-MS/MS method. Identification of the CYP2C19*2, CYP2C19*17, CYP3A4*1G, CYP1A2*1F, and ABCB1 C3435T genetic polymorphisms was performed by PCR-RFLP, while platelet reactivity units (PRU) were tested using the VerifyNow P2Y12 assay.
Results: There were significant differences in the pharmacokinetic parameters of the H4 active metabolite of CLP in the atorvastatin and rosuvastatin group divided according to their CYP2C19 genotype. There were no significant associations between CYP3A4, CYP1A2, and ABCB1 genotypes and pharmacokinetic parameters in either statin groups. In the multivariate analysis, CYP2C19*2 genotype and non-genetic factors including BMI, age, and diabetes significantly affected platelet reactivity in the studied groups of patients (P < 0.01). In the atorvastatin group, CYP2C19*2, CYP3A4*1G, and ABCB1 C3435T TT genotypes were independent determinants of PRU values (P < 0.01).
Conclusion: The CYP2C19*2 allele is the primary determinant of the exposition to the H4 active metabolite of clopidogrel and platelet reactivity in patients co-treated with atorvastatin or rosuvastatin.
MeSH term(s) Alleles ; Anticholesteremic Agents/therapeutic use ; Atorvastatin/therapeutic use ; Blood Platelets/drug effects ; Clopidogrel/pharmacokinetics ; Clopidogrel/therapeutic use ; Cytochrome P-450 Enzyme System/genetics ; Female ; Genotype ; Humans ; Isoenzymes/therapeutic use ; Male ; Middle Aged ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/pharmacokinetics ; Platelet Aggregation Inhibitors/therapeutic use ; Polymorphism, Genetic/genetics ; Rosuvastatin Calcium/therapeutic use
Chemical Substances Anticholesteremic Agents ; Isoenzymes ; Platelet Aggregation Inhibitors ; Rosuvastatin Calcium (83MVU38M7Q) ; Cytochrome P-450 Enzyme System (9035-51-2) ; Atorvastatin (A0JWA85V8F) ; Clopidogrel (A74586SNO7)
Language English
Publishing date 2020-01-02
Publishing country Germany
Document type Journal Article
ZDB-ID 121960-1
ISSN 1432-1041 ; 0031-6970
ISSN (online) 1432-1041
ISSN 0031-6970
DOI 10.1007/s00228-019-02822-x
Shelf mark
Zs.A 672: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top